Stock listing

NASDAQ:RNTX Rein Therapeutics, Inc. Stock

Home listing (NASDAQ) of Rein Therapeutics, Inc.

Follow Rein Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RNTX

$0.337 USD -0.018 (-5.2%)

Close on Nov 20, 2026

Past year -75.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.335 – $0.390 USDNov 20, 2026
Volume
668,573 sharesNov 20, 2026
Market cap
$29.06M USDAt the close on Nov 20, 2026 · price × 86.27M shares outstanding
52-week range
$0.284 – $2.100 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$371,699 USDMedian day 348,766 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Rein Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RNTX · Home$0.337 USD-0.018 (-5.2%)668,573$0.358$0.390$0.335$0.355Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.337-0.018-5.2%$0.358$0.390$0.335668,573
$0.355-0.001-0.3%$0.366$0.390$0.350815,803
$0.356-0.044-10.9%$0.380$0.405$0.3252,483,079
$0.400-0.152-27.5%$0.500$0.500$0.2848,481,447
$0.552-0.008-1.4%$0.551$0.574$0.501488,672
$0.560-0.046-7.6%$0.600$0.605$0.552348,766
$0.606+0.016+2.7%$0.602$0.626$0.591307,100
$0.590-0.031-5.0%$0.630$0.630$0.558528,000
$0.621+0.007+1.1%$0.624$0.650$0.586319,900
$0.614+0.002+0.3%$0.594$0.630$0.575408,700
$0.612-0.047-7.1%$0.650$0.655$0.572303,700
$0.659-0.009-1.3%$0.688$0.728$0.654213,900
$0.668+0.033+5.2%$0.668$0.705$0.634256,400
$0.635-0.035-5.2%$0.690$0.711$0.620392,700
$0.670-0.057-7.8%$0.700$0.700$0.660121,500
$0.727+0.012+1.7%$0.707$0.750$0.677189,000
$0.715+0.011+1.6%$0.697$0.741$0.660389,700
$0.704+0.121+20.8%$0.600$0.720$0.590622,100
$0.583+0.001+0.2%$0.570$0.609$0.560394,100
$0.582-0.020-3.3%$0.595$0.612$0.572331,300
$0.602-0.023-3.7%$0.620$0.624$0.590305,200
$0.625+0.030+5.0%$0.607$0.650$0.595266,100
$0.595+0.043+7.8%$0.545$0.607$0.543296,400
$0.552-0.038-6.4%$0.580$0.615$0.552502,200
$0.590-0.038-6.1%$0.613$0.622$0.570372,000
$0.628+0.042+7.2%$0.600$0.666$0.5511,372,900
$0.586-0.169-22.4%$0.755$0.755$0.5401,143,400
$0.755-0.030-3.8%$0.777$0.777$0.750142,500
$0.785-0.009-1.1%$0.770$0.788$0.750108,100
$0.794+0.025+3.3%$0.761$0.810$0.761307,500
$0.769-0.020-2.5%$0.784$0.784$0.746477,600
$0.789-0.036-4.4%$0.800$0.817$0.780447,000
$0.8250.0000.0%$0.825$0.834$0.809185,600
$0.825+0.024+3.0%$0.815$0.870$0.810336,100
$0.801-0.051-6.0%$0.850$0.863$0.780480,500
$0.852+0.048+6.0%$0.804$0.899$0.7591,108,000
$0.804+0.014+1.8%$0.800$0.826$0.762419,000
$0.790+0.069+9.6%$0.720$0.810$0.720388,400
$0.721-0.027-3.6%$0.763$0.790$0.720162,800
$0.748+0.004+0.5%$0.741$0.820$0.730112,800
$0.744-0.026-3.4%$0.770$0.785$0.715296,300
$0.770-0.025-3.1%$0.790$0.817$0.770441,400
$0.7950.0000.0%$0.807$0.821$0.79087,100
$0.795-0.005-0.6%$0.811$0.815$0.790178,200
$0.800+0.011+1.4%$0.792$0.820$0.780492,500
$0.789+0.087+12.4%$0.715$0.790$0.703262,700
$0.702-0.006-0.8%$0.710$0.740$0.700266,400
$0.708-0.083-10.5%$0.784$0.790$0.700556,100
$0.791+0.006+0.8%$0.801$0.845$0.750346,800
$0.785+0.004+0.5%$0.799$0.813$0.770295,600
$0.781-0.047-5.7%$0.820$0.835$0.772240,800
$0.828-0.035-4.1%$0.880$0.880$0.822265,300
$0.863-0.026-2.9%$0.930$0.960$0.850760,300
$0.889+0.045+5.3%$0.920$0.920$0.850984,800
$0.844+0.069+8.9%$0.790$0.870$0.790568,000
$0.775+0.022+2.9%$0.760$0.791$0.736489,100
$0.753+0.003+0.4%$0.749$0.765$0.729344,300
$0.750-0.012-1.6%$0.770$0.776$0.741546,100
$0.762-0.021-2.7%$0.788$0.788$0.762259,000
$0.783-0.017-2.1%$0.792$0.811$0.783136,500
$0.8000.0000.0%$0.810$0.824$0.780324,700
$0.8000.0000.0%$0.804$0.822$0.771276,754
$0.800-0.018-2.2%$0.820$0.824$0.770463,562
$0.818+0.024+3.0%$0.800$0.855$0.771580,000
$0.794+0.002+0.3%$0.856$0.877$0.7752,489,200

Splits

1 split · NASDAQ:RNTX · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:RNTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Rein Therapeutics, Inc. news

Rein Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 106 in all · newest Nov 16, 2026 · oldest 2020
Decks
4 decks · latest September 2026

Where Rein Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RNTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RNTXBOATSUnited StatesUSD
Tradegate:015ATradegateGermanyEUR

Valuation

Price/book 0.6× against a median of 4.5×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$6.43M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
2.11

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Rein Therapeutics, Inc. · NASDAQ:RNTXUS$29.06M−US$6.43Mn/an/an/a0.6×n/a0.0×2.11
Pacific Software, Inc. · OTC:PFSFUS$29.86MUS$38.10Mn/an/an/an/an/an/a1.57
NextCure, Inc. · NASDAQ:NXTCUS$29.53MUS$20.81Mn/an/an/a5.4×n/a0.0×1.85
NurExone Biologic Inc · TSXV:NRXUS$29.53MUS$28.52Mn/an/an/a23.3×n/a0.0×0.00
BioHarvest Sciences, Inc. · NASDAQ:BHSTUS$29.47MUS$34.54Mn/a1.0×n/a1.8×−34.7%1.0×0.43
Thiogenesis Therapeutics Corp · TSXV:TTIUS$29.28MUS$24.21Mn/an/an/a6.2×n/a0.0×0.37
NanoViricides, Inc. · AMEX:NNVCUS$29.11MUS$26.54Mn/an/an/a4.5×n/a0.0×1.82
Nicox SA · EURONEXT:ALCOXUS$29.05MUS$25.67Mn/a1.4×n/a3.8×−14.4%0.4×n/a
Serina Therapeutics, Inc. · AMEX:SERUS$28.45MUS$12.42Mn/a99.3×n/a2.0×n/a0.2×1.60
ProMIS Neurosciences Inc. · NASDAQ:PMNUS$28.43M−US$15.68Mn/an/an/a0.7×n/a0.0×0.83
Entropy Neurodynamics Limited · ASX:ENPUS$28.12MUS$24.43Mn/an/an/a5.8×n/a0.0×n/a
Median of the othersUS$29.20MUS$25.05M1.4×4.5×−24.5%0.0×1.20

Forecasts

1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
6.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.46 · 2 analysts

Team and board

Officers

OfficerRole
Brian WindsorPresident and CEO
Ron ChenVP, Finance and Corporate Controller
Tim CunninghamInterim Chief Financial Officer
Kristie LauterbachVP, Quality Assurance
Matt KarpenVP, CMC
Cory HogaboamChief Scientific Officer

Board

DirectorRole
Brian WindsorPresident and CEO

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−27.6%
Q2 2026Aug 14, 2026 · Before open+2.3%
Q1 2026May 15, 2026 · Before open−7.1%
Q3 2025Nov 14, 2025 · Before open−7.4%
Q2 2025Aug 14, 2025 · After close+3.4%
Q1 2025May 15, 2025 · After close−6.4%
Q3 2024Nov 14, 2024 · After close−13.3%
Q2 2024Aug 14, 2024 · After close−10.8%
Q1 2024May 15, 2024 · After close−1.3%
Q3 2023Oct 13, 2023 · After close+5.5%
All 20 quarters
QuarterResultsShare move
Q2 2023Aug 8, 20230.0%
Q1 2023May 8, 2023 · Before open+8.6%
Q4 2022Mar 20, 2023+2.9%
Q3 2022Nov 1, 2022 · Before open+2.5%
Q2 2022Aug 15, 2022 · After close+2.8%
Q1 2022May 5, 2022 · After close−0.7%
Q4 2021Mar 28, 2022−11.8%
Quarter to Sep 30, 2021Nov 12, 2021 · Before open−6.2%
Quarter to Jun 30, 2021Aug 11, 2021 · After close+8.0%
Quarter to Mar 31, 2021May 11, 2021 · After close+3.5%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2026)Technical55 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck32 slidesAugust 2026
Aileron Therapeutics — Merger or Acquisition (October 2023)Merger or acquisition40 slidesOct 31, 2023
Aileron Therapeutics — Corporate Update (June 2020)Corporate update6 slidesJun 1, 2020

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: US$50M · US$1 a share · Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC
Dealers: Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC (lead)
Use of proceeds: Fully fund the Phase 2 trial of LTI-03 in IPF through completion, plus working capital and general corporate purposes
Apr 30, 2026
Pre-paid advances repayable in common stock
Announced: up to US$6M
Buyers: Yorkville Advisors Global, LP (affiliate) (up to $6 million in pre-paid advances, initial $1 million funded at signing)
Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes
Jul 30, 2025
Common stock under standby equity purchase agreement
Announced: up to US$15M
Buyers: Yorkville Advisors Global, LP (affiliate) (up to $15 million of common stock over 36 months at Rein's option)
Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes
Jul 30, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as AILERON THERAPEUTICS INC. Priced at US$15.00 a share on Jun 28, 2017.

Price
US$15.00 a share
Shares offered
3,750,000 shares of common stock
Offering size
US$56.3 million
Underwriters' option
Up to 562,500 more shares
Underwriters
BofA Merrill Lynch, Jefferies, William Blair, Canaccord Genuity · In the order on the cover
Shares delivered
On or about Jul 5, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceSep 10, 2015
Filed publiclyJun 2, 2017
Amended onceJun 19, 2017
Shares registered with an exchangeJun 23, 2017
Declared effective by the SECJun 28, 2017
Final prospectus, with the priceJun 29, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Jun 29, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue1.00K63.0K
Gross profit-1.00K-63.0K
Research and development11.0M14.2M3.99M18.0M17.0M11.2M17.7M18.4M14.2M10.3M
Selling, general and administrative10.9M13.9M11.4K9.68K9.60K9.33K
Operating income-50.6M-65.1M-16.3M-27.6M-26.6M-20.5M-30.0M-31.9M-23.0M-18.2M
Depreciation and amortization1.00K63.0K119.0K169.0K121.0K163.0K155.0K218.0K129.0K232.0K
EBITDA-50.6M-65.0M-16.2M-27.5M-26.5M-20.3M-29.8M-31.7M-22.9M-17.9M
Income before tax-50.6M-64.3M-15.7K-27.3K-26.2K-21.2K
Income tax-712.0K-1.54M00000000
Net income-49.9M-62.9M-15.7M-27.3M-26.2M-27.3M-29.4M-31.5M-22.6M-18.1M
Earnings per share, basic-1.96-3.51-3.42-6.02-5.89-0.61-1.20-2.14-3.04-42.35
Earnings per share, diluted-1.96-3.51-3.42-6.02-5.89-0.61-1.20-2.14-3.04-42.35

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.21M12.9M17.3M5.19M3.60M7.05M5.31M10.6M11.9M20.7M
Short-term investments0016.0M42.3M6.76M13.0M10.1M38.9M0
Current assets4.33M13.7M18.3M21.9M48.2M16.3M19.6M21.8M51.8M21.1M
Property, plant and equipment01.00K19.0K70.0K128.0K15.0K295.0K7.29M154.0K107.0K
Goodwill6.33M6.33M6.33M0
Total assets24.2M62.2M106.0M22.0M48.5M16.3M26.5M30.3M52.7M22.0M
Accounts payable3.98M911.0K1.19M1.72M1.21M1.60M1.45M1.73M1.60M1.97M
Current liabilities6.18M5.75M4.38M3.38M4.51M3.96M5.84M5.37M4.89M4.07M
Long-term debt219.0K
Total debt48.0K33.0K162.0K387.0K5.03M5.34M
Total liabilities7.24M7.80M7.71M3.38M4.58M4.18M10.4M10.7M4.89M4.08M
Shareholders' equity16.9M54.4M98.3M18.6M43.9M12.2M16.0M19.6M47.8M-111.8M
Shares outstanding27.6M21.7M4.89M4.54M4.53M43.8M27.8M14.7M14.7M432.4K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-19.4M-22.3M-19.8M-24.9M-23.8M-20.5M-26.5M-27.9M-20.5M-15.0M
Capital spending0000-157.0K-5.00K-151.0K-4.42M-142.0K0
Free cash flow-19.4M-22.3M-19.8M-24.9M-23.9M-20.5M-26.6M-32.3M-20.7M-15.0M
Cash from investing016.2M26.5M-35.9M6.41M-2.81M24.7M-38.9M-25.0K
Cash from financing9.76M17.8M15.8M055.7M15.8M24.0M2.52M50.6M32.0M
Change in cash-9.65M-4.47M12.1M1.59M-4.01M1.74M-5.32M-723.0K-8.85M16.9M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 16, 2026Current reportSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportSep 4, 2026Current reportSEC
8-K · Current reportAug 27, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
8-K · Current reportJul 21, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 14, 2026Big-stake noticeSEC
All 527 filings
FilingDateTypeFiled with
ARS · Annual report to shareholdersJun 8, 2026Annual reportSEC
DEFA14A · Additional proxy materialJun 8, 2026Meeting noticeSEC
DEF 14A · Proxy statementJun 8, 2026Meeting noticeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementMay 28, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 8, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
8-K · Current reportMay 4, 2026Material contractSEC
424B5 · ProspectusMay 4, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 1, 2026Other filingsSEC
CORRESP · Letter to the SECApr 28, 2026Other filingsSEC
CORRESP · Letter to the SECApr 28, 2026Other filingsSEC
S-1 · Registration statementApr 28, 2026Offer documentSEC
10-K/A · Annual report, amendedApr 27, 2026Annual reportSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 2, 2026Material contractSEC
8-K · Current reportFeb 19, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportJan 16, 2026Material contractSEC
UPLOAD · Letter from the SECDec 31, 2025Other filingsSEC
DRS · Draft registration statementDec 29, 2025Offer documentSEC
8-K · Current reportDec 11, 2025Current reportSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025Current reportSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
8-K · Current reportOct 24, 2025Material contractSEC
8-K · Current reportOct 9, 2025Current reportSEC
3 · Initial statement of ownershipOct 3, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 26, 2025Big-stake noticeSEC
8-K · Current reportSep 22, 2025Current reportSEC
8-K · Current reportSep 9, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveSep 8, 2025Other filingsSEC
CORRESP · Letter to the SECSep 4, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 4, 2025Other filingsSEC
S-1 · Registration statementSep 3, 2025Offer documentSEC
8-K · Current reportAug 19, 2025Current reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportJul 30, 2025Material contractSEC
424B5 · ProspectusJul 30, 2025Offer documentSEC
424B5 · ProspectusJul 30, 2025Offer documentSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
8-K · Current reportJul 23, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialJul 11, 2025Meeting noticeSEC
8-K · Current reportJul 11, 2025Current reportSEC
DEFA14A · Additional proxy materialJun 24, 2025Meeting noticeSEC
8-K · Current reportJun 24, 2025Current reportSEC
8-K · Current reportJun 12, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMay 23, 2025Other filingsSEC
CORRESP · Letter to the SECMay 21, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 21, 2025Other filingsSEC
S-3 · Registration statementMay 16, 2025Offer documentSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
424B5 · ProspectusMay 15, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersMay 12, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 12, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 12, 2025Meeting noticeSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
8-K · Current reportApr 22, 2025Material contractSEC
8-K · Current reportApr 17, 2025Current reportSEC
10-K · Annual reportApr 7, 2025Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
8-K · Current reportJan 10, 2025Current reportSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2024Big-stake noticeSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
8-K · Current reportAug 21, 2024Meeting outcomeSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportJul 26, 2024Material contractSEC
424B5 · ProspectusJul 26, 2024Offer documentSEC
424B5 · ProspectusJul 26, 2024Offer documentSEC
ARS · Annual report to shareholdersJul 9, 2024Annual reportSEC
DEFA14A · Additional proxy materialJul 9, 2024Meeting noticeSEC
DEF 14A · Proxy statementJul 9, 2024Meeting noticeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 5, 2024Current reportSEC
3 · Initial statement of ownershipMay 16, 2024Insider tradeSEC
8-K · Current reportMay 16, 2024Management or board changeSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
4/A · Change in ownership, amendedMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
8-K · Current reportMay 1, 2024Material contractSEC
424B5 · ProspectusMay 1, 2024Offer documentSEC
S-8 · Registration statement for employee plansMay 1, 2024Offer documentSEC
FWP · Free writing prospectusMay 1, 2024Offer documentSEC
8-K · Current reportMay 1, 2024ResultsSEC
3 · Initial statement of ownershipApr 30, 2024Insider tradeSEC
144 · Notice of proposed saleApr 29, 2024Other filingsSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
SC 13D/A · Big-stake notice, amendedApr 16, 2024Big-stake noticeSEC
8-K · Current reportApr 15, 2024ResultsSEC
10-K · Annual reportApr 15, 2024Annual reportSEC
4/A · Change in ownership, amendedApr 10, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 10, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 2, 2024Insider tradeSEC
NT 10-K · Late filing noticeApr 1, 2024Explanation requestSEC
8-K · Current reportMar 29, 2024Management or board changeSEC
8-K · Current reportMar 15, 2024Management or board changeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
SC 13G · Big-stake noticeMar 5, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMar 5, 2024Big-stake noticeSEC
8-K · Current reportMar 1, 2024Management or board changeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
8-K · Current reportFeb 29, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 13, 2024Management or board changeSEC
EFFECT · Notice that a registration is effectiveFeb 6, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 5, 2024Big-stake noticeSEC
CORRESP · Letter to the SECFeb 1, 2024Other filingsSEC
UPLOAD · Letter from the SECFeb 1, 2024Other filingsSEC
DEFA14A · Additional proxy materialJan 31, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansJan 29, 2024Offer documentSEC
S-3 · Registration statementJan 29, 2024Offer documentSEC
ARS · Annual report to shareholdersJan 29, 2024Annual reportSEC
DEF 14A · Proxy statementJan 29, 2024Meeting noticeSEC
8-K · Current reportJan 29, 2024Current reportSEC
8-K · Current reportJan 25, 2024Current reportSEC
PRE 14A · Preliminary proxy statementJan 19, 2024Meeting noticeSEC
8-K/A · Current report, amendedJan 11, 2024Current reportSEC
8-K · Current reportJan 10, 2024Current reportSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
DNov 16, 2023Other filingsSEC
SC 13G · Big-stake noticeNov 13, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 3, 2023Big-stake noticeSEC
4 · Change in ownershipNov 2, 2023Insider tradeSEC
4 · Change in ownershipNov 2, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 2, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 2, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 2, 2023Insider tradeSEC
8-K · Current reportOct 31, 2023Acquisition or disposalSEC
10-Q · Quarterly reportOct 13, 2023Quarterly reportSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
10-Q · Quarterly reportMay 8, 2023Quarterly reportSEC
10-K/A · Annual report, amendedApr 28, 2023Annual reportSEC
10-K · Annual reportMar 20, 2023Annual reportSEC
8-K · Current reportFeb 23, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
8-K · Current reportNov 10, 2022Current reportSEC
10-Q · Quarterly reportNov 1, 2022Quarterly reportSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportJul 8, 2022Management or board changeSEC
8-K · Current reportJun 29, 2022Current reportSEC
424B5 · ProspectusJun 21, 2022Offer documentSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
4 · Change in ownershipJun 17, 2022Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 17, 2022Other filingsSEC
8-K · Current reportJun 16, 2022Management or board changeSEC
CORRESP · Letter to the SECJun 14, 2022Other filingsSEC
UPLOAD · Letter from the SECJun 14, 2022Other filingsSEC
DEL AMJun 13, 2022Other filingsSEC
8-K · Current reportJun 8, 2022Current reportSEC
S-3 · Registration statementJun 7, 2022Offer documentSEC
8-K · Current reportJun 7, 2022Management or board changeSEC
10-Q · Quarterly reportMay 5, 2022Quarterly reportSEC
8-K · Current reportApr 29, 2022Management or board changeSEC
DEFA14A · Additional proxy materialApr 29, 2022Meeting noticeSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Rein Therapeutics, Inc.’s releases · as of Nov 12, 2026

Common shares
86,267,032
Fully diluted
86,267,032

Fully diluted

LineSharesAs of
Common shares86,267,032Nov 12, 2026

Share count over time

CountShares
Nov 12, 202686,267,032
Sep 30, 202686,267,032

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Voss Capital, LP5.85M6.8%US$4.7MSep 30, 2026
Cable Car Capital, LP5.2M6.0%US$4.18MSep 30, 2026
ADAR1 Capital Management, LLC4.5M5.2%US$3.62MSep 30, 2026
Vanguard3.9M4.5%US$3.13MSep 30, 2026
BIOS Capital Management, LP2.98M3.5%US$2.4MSep 30, 2026
Ikarian Capital, LLC2.95M3.4%US$2.37MSep 30, 2026
Citadel2.57M3.0%US$2.06MSep 30, 2026
Velan Capital Investment Management LP1.7M2.0%US$1.37MSep 30, 2026
Great Point Partners LLC1.66M1.9%US$1.34MSep 30, 2026
Prosight Management, LP1.66M1.9%US$1.33MSep 30, 2026
All 62 holders
HolderSharesOf the companyValueAs of
Senvest Management, LLC1.23M1.4%US$990KSep 30, 2026
Bleichroeder LP1M1.2%US$804KSep 30, 2026
Boothbay Fund Management, LLC889K1.0%US$715KSep 30, 2026
Geode Capital833K0.97%US$670KSep 30, 2026
University Of Texas/Texas Am Investment Management Co512K0.59%US$411KSep 30, 2026
State Street380K0.44%US$305KSep 30, 2026
Texas Capital Bank Wealth Management Services Inc361K0.42%US$290KSep 30, 2026
Sigma Planning Corp357K0.41%US$287KSep 30, 2026
BlackRock322K0.37%US$259KSep 30, 2026
Sequoia Financial Advisors, LLC235K0.27%US$189KSep 30, 2026
Gagnon Securities LLC229K0.27%US$184KSep 30, 2026
Palogic Value Management, L.P.180K0.21%US$145KSep 30, 2026
ABS Investment Management LLC175K0.20%US$141KSep 30, 2026
Rock Creek Group LLC175K0.20%US$141KSep 30, 2026
Northern Trust160K0.19%US$128KSep 30, 2026
Marshall Wace, LLP158K0.18%US$127KSep 30, 2026
XTX Topco Ltd121K0.14%US$97,451Sep 30, 2026
Warberg Asset Management LLC96,0000.11%US$78,038Sep 30, 2026
Rossby Financial, LCC91,4000.11%US$73,486Sep 30, 2026
Savant Capital, LLC61,0560.07%US$49,090Sep 30, 2026
Mercer Global Advisors Inc50,4610.06%US$40,571Sep 30, 2026
Northwestern Mutual Wealth Management Co42,4400.05%US$34,122Sep 30, 2026
Americana Partners, LLC41,8400.05%US$33,639Sep 30, 2026
UBS39,7820.05%US$31,985Sep 30, 2026
SteelPeak Wealth, LLC33,0000.04%US$26,532Sep 30, 2026
Prime Capital Investment Advisors, LLC31,1110.04%US$25,013Sep 30, 2026
Ancora Advisors LLC30,0000.03%US$24,120Sep 30, 2026
Sfmg, LLC30,0000.03%US$24,120Sep 30, 2026
Chicago Partners Investment Group LLC29,9280.03%US$17,421Sep 30, 2026
Meridian Wealth Advisors, LLC28,4860.03%US$22,903Sep 30, 2026
Jane Street27,6280.03%US$22,213Sep 30, 2026
Hrt Financial LP23,6660.03%US$19,000Sep 30, 2026
Gleason Group, Inc.22,3890.03%US$18,001Sep 30, 2026
Cetera Investment Advisers21,7420.03%US$17,481Sep 30, 2026
Sanders Morris Harris LLC20,0000.02%US$16,080Sep 30, 2026
Global Retirement Partners, LLC19,3160.02%US$15,530Sep 30, 2026
Cane Capital Partners, LLC18,0000.02%US$14,472Sep 30, 2026
Certuity, LLC17,5000.02%US$14,070Sep 30, 2026
Renaissance Technologies15,0830.02%US$12,127Sep 30, 2026
Annandale Capital, LLC15,0260.02%US$12,081Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.52M2.9%US$2.62MJun 30, 2026
Vanguard Extended Market Index Fund786K0.91%US$817KJun 30, 2026
Fidelity Extended Market Index Fund132K0.15%US$146KMay 31, 2026
iShares Micro-Cap ETF87,0650.10%US$90,548Jun 30, 2026
Fidelity Nasdaq Composite Index ETF75,5710.09%US$83,884May 31, 2026
Vanguard Balanced Index Fund43,3680.05%US$45,103Jun 30, 2026
Fidelity Total Market Index Fund35,2420.04%US$39,119May 31, 2026
Fidelity Series Total Market Index Fund29,9850.03%US$33,283May 31, 2026
Vanguard Institutional Total Stock Market Index Fund26,0980.03%US$27,142Jun 30, 2026
Fidelity Nasdaq Composite Index Fund8,122<0.01%US$9,015May 31, 2026
All 11 holders
HolderSharesOf the companyValueAs of
1290 VT Micro Cap Portfolio5,739<0.01%US$5,969Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Von Rickenbach Josef H
Director
Buy4,500USD 1.07US$4,815May 27, 2026
Von Rickenbach Josef H
Director
Buy23,190USD 1.06US$24,581May 26, 2026
Von Rickenbach Josef H
Director
Buy15,950USD 1.05US$16,748May 22, 2026
Von Rickenbach Josef H
Director
Buy3,420USD 1.04US$3,557May 21, 2026
Windsor James Brian
Director, Officer: See Remarks
Buy25,000USD 1.00US$25,000Apr 30, 2026

Big stakes

StakeStakeSharesDateFiling
BIOS CAPITAL MANAGEMENT, LP9.99%7.8MMay 6, 2026Schedule 13G
Funicular Funds, LP6.70%5.2MMay 1, 2026Schedule 13G
Voss Capital, LP6.60%5.66MJun 30, 2026Schedule 13G
ADAR1 Capital Management, LLC5.30%4.5MJun 30, 2026Schedule 13G
Lynwood Capital Management Inc.5.00%4.28MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
William C. Fairey
Other companies: Ascendis Pharma A/S (Director · Since at least Mar 18, 2026); KalVista Pharmaceuticals, Inc. (Director · Since at least Apr 18, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2021); MyoKardia Inc (EVP, Chief Commercial Officer · Jan 28, 2019 – Nov 17, 2020 · Past); ChemoCentryx Inc. (Chief Operating Officer · Jan 3, 2018 – Jan 3, 2018 · Past)
Director · Since at least Oct 31, 2023
Muneer A Satter
Other companies: Annexon, Inc. (Director · Since at least Jul 23, 2020); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 18, 2019 · Past); Immunic, Inc. (Director · Apr 16, 2014 – Sep 13, 2018 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past)
See Remarks, Director · Jun 8, 2020 – Jan 8, 2021 · Past
Timothy M Cunningham
Other companies: Neuphoria Therapeutics Inc. (Chief Financial Officer · Jul 1, 2024 – Jul 1, 2024 · Past); Alaunos Therapeutics, Inc. (interim CFO · Feb 17, 2021 – Feb 17, 2021 · Past); Organogenesis Holdings Inc. (Chief Financial Officer · Dec 10, 2018 – Apr 22, 2020 · Past)
See Remarks · May 16, 2024 – May 16, 2024 · Past
Brian M Gallagher Jr
Other companies: eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Jun 13, 2024 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Jul 2, 2018 · Past)
Director · Jun 28, 2017 – Jul 25, 2017 · Past
James Brian Windsor
Other companies: TFF Pharmaceuticals Inc (Chief Science Officer, Director · Oct 24, 2019 – Dec 7, 2020 · Past)
See Remarks, Director · Since at least Oct 31, 2023
Kathryn Gregory
Other companies: Longevity Health Holdings, Inc. (Director · Jul 14, 2023 – Oct 11, 2024 · Past)
SVP, Chief Business Officer · Feb 25, 2019 – Jan 31, 2020 · Past
Rick Wanstall
Other companies: Oncorus Inc (CFO and Treasurer · May 10, 2022 – May 25, 2022 · Past)
See Remarks · Mar 27, 2019 – Mar 30, 2022 · Past
Tim Cunningham
Other companies: Neuphoria Therapeutics Inc. (Fractional CFO · Since at least Nov 4, 2026)
Interim Chief Financial Officer · Since at least Nov 4, 2026
Brian WindsorPresident and CEO · Since at least Nov 2, 2026
Caleb Maxfield WinderDirector · Jun 28, 2017 – Jun 21, 2018 · Past
All 18 people
PersonSeat
Cory HogaboamChief Scientific Officer · Since at least Aug 4, 2026
Kira NelsonSee Remarks · Jun 28, 2017 – Jul 25, 2017 · Past
Kristie LauterbachVP, Quality Assurance · Since at least Nov 5, 2026
Matt KarpenVP, CMC · Since at least Nov 4, 2026
Nolan Howard SigalDirector · Apr 2, 2019 – Jun 15, 2022 · Past
Reinhard J AmbrosDirector · Since at least Jun 28, 2017
Ron ChenVP, Finance and Corporate Controller · Since at least Nov 4, 2026
Scott KapnickDirector · Aug 14, 2018 – Aug 14, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about Rein Therapeutics, Inc.